Cancer Center Support Grant (CCSG)

癌症中心支持补助金 (CCSG)

• 批准号: 8089819
• 负责人: Michael B Kastan
• 金额: $ 10万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8089819
• 关键词: American; Area; Biology; Brain Neoplasms; Cancer Center; Cancer Center Support Grant; Cancer Control; Catastrophic Illness; Charities; Chemicals; Child; Clinical Research; Clinical Trials; Developmental Therapeutics Program; Epidemiology; Extramural Activities; Foundations; Funding; Hematologic Neoplasms; Hospitals; Immunology; Interdisciplinary Study; Laboratories; Lead; Leadership; Malignant Childhood Neoplasm; Malignant Neoplasms; Mission; Neurobiology; Organizational Change; Patients; Population Sciences; Process; Publications; Recording of previous events; Research; Research Infrastructure; Research Personnel; Resource Sharing; Resources; Saint Jude Children' s Research Hospital; Science; Scientist; Signal Transduction; Solid; Strategic Planning; Structure; Translations; anticancer research; authority; cancer prevention; cancer research center director; clinical application; follow-up; member; molecular oncology; multidisciplinary; patient population; programs

DESCRIPTION (provided by applicant): The mission of St. Jude Children's Research Hospital is to find cures for children with catastrophic illnesses through research and treatment. The resources of the hospital have been focused on pediatric cancer throughout its 44 year history and the Cancer Center has been supported by a CCSG for 29 years. Through the support of the American Lebanese Syrian Associated Charities (ALSAC), a separate corporation whose only purpose is to raise money in support of St. Jude Children's Research Hospital, patients are accepted without regard to ability to pay. Public support of the hospital through ALSAC provides a strong foundation for our Cancer Center upon which extramurally funded research and CCSG support can be leveraged to their fullest potential. In the current application, six multidisciplinary research programs are described. The Molecular Oncology (MO) and Signal Transduction (ST) Programs focus on basic, discovery-oriented research. The Developmental Therapeutics for Solid Malignancies (DTSM), Hematologic Malignancies (HM), Neurobiology and Brain Tumor (NBT), and Cancer Prevention and Control (CPC) Programs emphasize the translation of laboratory or population science to clinical application. The latter program is new to this application and represents the culmination of a long-standing commitment to long-term follow-up of our patient population, a recent commitment to population sciences, and successful recruitment of a world-class scientist to lead efforts in this area. Research by the 139 members of the Cancer Center is supported by 12 Shared Resources and an outstanding clinical research infrastructure. During the previous funding period, a new Cancer Center Director was appointed and the overall structure of our Cancer Center and its leadership were enhanced by several organizational changes, including bringing the infrastructure supporting the expansive clinical trials efforts administratively under the Cancer Center's authority. Several Program leader changes and the successful recruitment of three new outstanding Department Chairs (Immunology, Chemical Biology, and Epidemiology/Cancer Control) during the last funding period significantly enhance the multidisciplinary science done by our Cancer Center Programs. St. Jude Cancer Center investigators had over 2000 cancer-related publications during the funding period, 20% of which represented intraprogrammatic interactions and 15% of which were inter-programmatic. Extramural support for cancer research done at St. Jude is currently over $50 million per year, $31 million of which is from the NCI/HHMI. St. Jude Children's Research Hospital recently went through a vigorous Strategic Planning process and made a strong and long-term commitment to remain focused on cancer research.

描述（由申请人提供）：圣裘德儿童研究医院的任务是通过研究和治疗为患有灾难性疾病的儿童找到治疗方法。在整个44年的历史中，医院的资源一直集中在儿科癌症上，癌症中心得到了29年的CCSG支持。通过由美国黎巴嫩叙利亚相关慈善机构（ALSAC）的支持，这是一家独立的公司，其唯一目的是筹集资金来支持圣裘德儿童研究医院，而不考虑付款能力而被接受。通过ALSAC对医院的公众支持为我们的癌症中心提供了坚实的基础，在该中心上，可以利用其最大的潜力来利用外部资助的研究和CCSG支持。在当前的应用程序中，描述了六个多学科研究计划。分子肿瘤学（MO）和信号转导（ST）计划着眼于基本的，面向发现的研究。固体恶性肿瘤（DTSM），血液系统恶性肿瘤（HM），神经生物学和脑肿瘤（NBT）以及癌症预防与控制（CPC）计划的发育疗法强调了实验室或人口科学向临床应用的翻译。后一个计划是该应用程序的新事物，代表了长期对患者人群的长期随访，最近对人口科学的承诺以及成功招募世界一流科学家在这一领域领导努力的长期承诺的高潮。癌症中心139名成员的研究得到了12个共享资源和出色的临床研究基础设施的支持。在上一个资金期间，任命了新的癌症中心主任，我们的癌症中心的整体结构及其领导层通过几项组织变更增强，包括在癌症中心的权威下，将基础设施带来了支持广泛的临床试验工作的基础设施。在上一个资金期间，几个计划负责人的变化以及成功招募了三个新的杰出部门主席（免疫学，化学生物学和流行病学/癌症控制），从而大大增强了我们的癌症中心计划所做的多学科科学。在资金期间，圣裘德癌症中心的研究人员拥有2000多个与癌症相关的出版物，其中20％代表了术中的相互作用，其中15％是跨编程间的。在圣裘德进行的癌症研究的壁外支持目前每年超过5000万美元，其中3100万美元来自NCI/HHMI。圣裘德儿童研究医院最近经历了一个剧烈的战略计划过程，并做出了坚定而长期的承诺，致力于专注于癌症研究。